Technical analysis for Greenwich Lifesciences Inc. GLSI including support levels resistance levels and stop losses for GLSI ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Greenwich LifeSciences (GLSI – Research Report) ...

Purcell & Lefkowitz LLP announces that it is investigating Greenwich LifeSciences, Inc. on behalf of the company's shareholders.  The investigation seeks to determine whether Greenwich LifeSciences's ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase ...

Check the time stamp on this data. Updated AI-Generated Signals for Greenwich Lifesciences Inc. (GLSI) available here: GLSI.

Greenwich LifeSciences (GLSI) announced an update on FLAMINGO-01 open label HLA data. Analysis of the open label data from FLAMINGO-01 has ...

Greenwich LifeSciences, Inc.'s main program, GLSI-100, faces challenges in proving its benefit over existing HER2-positive breast cancer treatments, with ongoing phase 3 trial results expected by ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

Snehal Patel, the CEO and CFO of $GLSI ($GLSI), bought 2,500 shares of the company on 01-10-2025. This trade was reported by Quiver Quantitative using data from a ...

ThoughtFocus, Inc. ("ThoughtFocus" or the "Company"), a leading provider of digital services and technology-enabled operations specializing in the financial services industry, is proud to announce ...

The European Medicines Agency (EMA) has approved the expansion of Greenwich LifeSciences’ Phase III FLAMINGO-01 breast cancer ...

STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating ...